These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10165529)

  • 1. Sensitivity analysis in health economic and pharmacoeconomic studies. An appraisal of the literature.
    Agro KE; Bradley CA; Mittmann N; Iskedjian M; Ilersich AL; Einarson TR
    Pharmacoeconomics; 1997 Jan; 11(1):75-88. PubMed ID: 10165529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality assessment of economic evaluations in selected pharmacy, medical, and health economics journals.
    Bradley CA; Iskedjian M; Lanctôt KL; Mittmann N; Simone C; St Pierre E; Miller E; Blatman B; Chabursky B; Einarson TR
    Ann Pharmacother; 1995; 29(7-8):681-9. PubMed ID: 8520080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality assessment of pharmacoeconomic abstracts of original research articles in selected journals.
    Trakas K; Addis A; Kruk D; Buczek Y; Iskedjian M; Einarson TR
    Ann Pharmacother; 1997 Apr; 31(4):423-8. PubMed ID: 9101002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Evaluation of Hospital and Community Pharmacy Services.
    Gammie T; Vogler S; Babar ZU
    Ann Pharmacother; 2017 Jan; 51(1):54-65. PubMed ID: 27586430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PHARMACOECONOMIC STUDIES IN WORLD HEALTH ORGANIZATION EASTERN MEDITERRANEAN COUNTRIES: REPORTING COMPLETENESS.
    Alefan Q; Rascati K
    Int J Technol Assess Health Care; 2017 Jan; 33(2):215-221. PubMed ID: 28578712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporation of future costs in health economic analysis publications: current situation and recommendations for the future.
    Gros B; Soto Álvarez J; Ángel Casado M
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):465-9. PubMed ID: 25737028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interpretation of "cost-effective" and soundness of economic evaluations in the pharmacy literature.
    Lee JT; Sanchez LA
    Am J Hosp Pharm; 1991 Dec; 48(12):2622-7. PubMed ID: 1814204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence of pharmacoeconomic studies to national guidelines in the Netherlands.
    Atthobari J; Bos JM; Boersma C; Brouwers JR; de Jong-van den Berg LT; Postma MJ
    Pharm World Sci; 2005 Oct; 27(5):364-70. PubMed ID: 16341742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of pharmacoeconomic research in China: A systematic review.
    Ma H; Jian W; Xu T; He Y; Rizzo JA; Fang H
    Medicine (Baltimore); 2016 Oct; 95(41):e5114. PubMed ID: 27741131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Systematic Review on the Extent and Quality of Pharmacoeconomic Publications for China.
    Jiang S; Ma X; Desai P; Yang L; Rascati K
    Value Health Reg Issues; 2014 May; 3():79-86. PubMed ID: 29702942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomic studies in Italy: a critical review of the literature.
    Cornago D; Li Bassi L; De Compadri P; Garattini L
    Eur J Health Econ; 2007 Jun; 8(2):89-95. PubMed ID: 17186206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluations in Italy: a review of the literature.
    Garattini L; De Compadri P; Clemente R; Cornago D
    Int J Technol Assess Health Care; 2003; 19(4):685-91. PubMed ID: 15095774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis: Problems with Russian Publications.
    Verbitskaya EV
    Int J Risk Saf Med; 2015; 27 Suppl 1():S89-90. PubMed ID: 26639728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The state of health economic evaluation research in Nigeria: a systematic review.
    Gavaza P; Rascati KL; Oladapo AO; Khoza S
    Pharmacoeconomics; 2010; 28(7):539-53. PubMed ID: 20550221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of pharmacoeconomic studies: utilization of a checklist.
    Sacristán JA; Soto J; Galende I
    Ann Pharmacother; 1993 Sep; 27(9):1126-33. PubMed ID: 8219449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging standardization in pharmacoeconomics.
    Mullins CD; Ogilvie S
    Clin Ther; 1998; 20(6):1194-202; discussion 1192-3. PubMed ID: 9916612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A critical review of the full economic evaluations of pharmacological treatments for glaucoma.
    Koleva D; De Compadri P; Virgili G; Nobili A; Garattini L
    J Med Econ; 2008; 11(4):719-41. PubMed ID: 19450078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic Review and Quality Evaluation of Pharmacoeconomic Studies on Traditional Chinese Medicines.
    Yang N; Zhang H; Deng T; Guo JJ; Hu M
    Front Public Health; 2021; 9():706366. PubMed ID: 34414159
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.